BioSpace News Archive

The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.

Knopp Biosciences LLC today announced the publication of a report that a Phase 2 study of dexpramipexole met its co-primary endpoints

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2018.

-- Presentations Highlight Versatility of Decipher Tests and Decipher GRID Technology Platform --

Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EDT Today

Dr. Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the Interim CEO and will remain as an advisor to the Company.

ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June

First-Quarter Revenue of $494.0 Million

$1.6 billion transaction will bolster Lilly’s clinical portfolio with ARMO’s lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types

AstraZeneca today announced that Health Canada has approved Lynparza® (olaparib) tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting